TOKYO, Mar 27 (Pulse News Wire) – Heartseed Inc. (219A.T) disclosed significant advancements in its LAPiS clinical trials aimed at treating severe heart failure patients.
The study demonstrated notable improvements in key metrics such as left ventricular end-diastolic volume (LVEDV) and left ventricular ejection fraction (LVEF). Notably, three out of five high-dose group patients showed substantial reductions in LVEDV and increases in LVEF post-treatment, indicating improved cardiac function. Additionally, the company highlighted that none of the patients experienced adverse events requiring hospital readmission, showcasing the therapy's safety profile.
Heartseed plans to leverage these findings to enhance the development of its next-generation product, HS-005, and advance its global expansion strategy. In terms of financials, Heartseed reported robust cash reserves totaling ¥7.676 billion as of December 2025, supporting ongoing research and development efforts. The company expects to allocate funds raised through its initial public offering (IPO) towards further clinical trials and operational management expenses, aiming to secure regulatory approval and commence sales.
🟢 Confidence: High AI-translated content.